by Tom Wilemon, Vanderbilt University Immune checkpoint therapy has revolutionized cancer therapy, leading to long-term remission for patients with advanced cancer. However, most cancer patients either do not respond or have only short-term responses to checkpoint therapy, which targets inhibitory receptors on T cells. A study published June 17 in Nature offers clues as to why blocking inhibitory receptors on tumor-infiltrating T cells may not always work....